Johnson & Johnson (BSP:JNJB34)
R$ 90.85 -3.1 (-3.3%) Market Cap: 3.33 Tn Enterprise Value: 3.47 Tn PE Ratio: 31.18 PB Ratio: 7.63 GF Score: 80/100

Johnson & Johnson at Wells Fargo Healthcare Conference Transcript

Sep 09, 2026 / 03:00PM GMT
Lawrence Biegelsen
Wells Fargo Securities LLC - Analyst

Welcome back, and good morning. I'm Larry Biegelsen, the MedTech analyst at Wells Fargo. It's my pleasure to host the next fireside chat with the management team from Johnson & Johnson. With us, we have Tim Schmid, Executive Vice President and Worldwide Chairman, MedTech. It's, as I said, fireside chat.

Tim, thanks for being here again.

Tim Schmid
Johnson & Johnson - Executive Vice President, Worldwide Chairman of MedTech

My pleasure, Larry, and thank you for the opportunity to represent J&J.

Questions & Answers

Lawrence Biegelsen;Tim Schmid
Wells Fargo Securities LLC - Analyst;Johnson & Johnson - Executive Vice President,

So let's start with a couple of big-picture questions. At your last Investor Day, I think it was December 2023. You had a goal to grow at the high end of MedTech, which you pegged at 5% to 7%. How has the market perform relative to your expectations? And how are you doing?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot